Physician profile
Jillian Johnson
NPI 1336841881
$7,621.52
in general payments reported to CMS, 2019-2025
52 companies · $4,010 in 2025
The $4,010 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $915 · 2024: $2,696 · 2025: $4,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,974 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,973.85 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $367.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,702.27 | 2023-2025 | |
| Janssen Biotech, INC. | $741.61 | 2023-2025 | Darzalex, Erleada, Rybrevant |
| Pharmaessentia USA Corporation | $327.33 | 2023-2025 | Besremi |
| Pfizer INC. | $310.32 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $277.47 | 2024-2025 | Imfinzi, Calquence, Enhertu |
| Stemline Therapeutics INC. | $264.07 | 2023-2025 | Orserdu |
| Incyte Corporation | $225.98 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $214.15 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Sobi, INC | $213.68 | 2023-2025 | |
| Genzyme Corporation | $211.70 | 2023-2025 | |
| Astellas Pharma US INC | $199.34 | 2023-2025 | Xtandi |
| Lilly USA, LLC | $193.36 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $187.29 | 2023-2025 | Libtayo, Lynozyfic |
| Galt Pharmaceuticals, LLC | $165.75 | 2023 | Orphengesic Forte |
| Eisai INC. | $163.13 | 2023-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $153.63 | 2024-2025 | Reblozyl, Opdivo |
| Genmab U.S., INC. | $143.43 | 2023-2025 | Epkinly |
| Merck Sharp & Dohme LLC | $139.22 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $125.87 | 2024-2025 | Tecentriq, Polivy, Tecentriq Hybreza |
| Puma Biotechnology, INC. | $118.42 | 2023-2025 | Nerlynx |
| Jazz Pharmaceuticals INC. | $91.26 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $90.38 | 2024-2025 | Monoferric |
| Servier Pharmaceuticals LLC | $89.97 | 2024-2025 | |
| Emd Serono, INC. | $88.31 | 2023-2025 | Bavencio |
| Seagen INC. | $87.48 | 2023 | Adcetris, Padcev |
| Array Biopharma INC | $83.81 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Sumitomo Pharma America, INC. | $79.49 | 2024-2025 | Orgovyx |
| Daiichi Sankyo INC. | $71.27 | 2024-2025 | Enhertu, Datroway |
| Beigene USA, INC. | $70.21 | 2024-2025 | Brukinsa, Tevimbra |
| Novocure INC. | $63.81 | 2025 | Optune Lua (Novottf-200t) |
| Abbvie INC. | $60.89 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $53.26 | 2024 | Xpovio |
| Exelixis INC. | $51.09 | 2025 | Cabometyx |
| Atland Pharmaceuticals, LLC | $48.84 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Blueprint Medicines Corporation | $48.67 | 2025 | Ayvakit |
| Beone Medicines USA, INC. | $46.63 | 2025 | Brukinsa, Tevimbra |
| Agios Pharmaceuticals, INC. | $40.36 | 2025 | Pyrukynd |
| Myriad Genetic Laboratories, INC. | $40.33 | 2023-2024 | Bracanalysis Cdx |
| Spectrum Pharmaceuticals INC. | $32.38 | 2024-2025 | Rolvedon |
| Rigel Pharmaceuticals, INC. | $32.11 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Alexion Pharmaceuticals, INC. | $31.06 | 2024 | Ultomiris |
| Geron Corporation | $30.40 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $30.13 | 2024 | |
| Iovance Biotherapeutics, INC. | $26.35 | 2024 | Amtagvi |
| Progenics Pharmaceuticals, INC. | $26.21 | 2023 | Pylarify |
| Emmaus Medical, INC. | $26.16 | 2024 | Endari |
| Alnylam Pharmaceuticals INC. | $17.60 | 2025 | Givlaari |
| Kite Pharma, INC. | $17.57 | 2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $17.54 | 2024 | Qinlock |
| Recordati_rare_diseases_inc. | $17.39 | 2025 | Sylvant |
| Adaptive Biotechnologies Corporation | $16.87 | 2024 | Clonoseq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.67 | 2025 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.